These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 34080386)

  • 1. [Management of metastatic hormone-naive prostate cancer at diagnosis].
    Colassin A; Denis C; Hermesse J; Waltregny D; Sautois B
    Rev Med Liege; 2021 May; 76(5-6):496-501. PubMed ID: 34080386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S; Lang JM; Jarrard DF
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of metastatic, castration-resistant prostate cancer].
    von Amsberg G; Merseburger AS
    Urologe A; 2020 Jun; 59(6):673-679. PubMed ID: 32274540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combination therapy for metastatic hormone-sensitive prostate cancer: What? When? For whom?].
    Thomas C; Ohlmann CH
    Urologe A; 2020 Jun; 59(6):665-672. PubMed ID: 32274544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
    Buonerba C; Ferro M; Dolce P; Crocetto F; Verde A; Lucarelli G; Scafuri L; Facchini S; Vaia A; Marinelli A; Terracciano D; Montella L; Longo N; Imbimbo C; Mirone V; Di Lorenzo G; De Placido S; Sonpavde G
    Crit Rev Oncol Hematol; 2020 Jul; 151():102992. PubMed ID: 32474391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate Cancer Drug Therapy: What Have Clinicians Missed During the COVID-19 Pandemic.
    Rahnama'i MS
    Am J Mens Health; 2022; 16(4):15579883221115593. PubMed ID: 35950609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].
    Wülfing C; Bögemann M; Goebell PJ; Hammerer P; Machtens S; Pfister D; Schwentner C; Steuber T; von Amsberg G; Schostak M
    Urologe A; 2019 Sep; 58(9):1066-1072. PubMed ID: 31041460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    Rodriguez-Vida A; Galazi M; Rudman S; Chowdhury S; Sternberg CN
    Drug Des Devel Ther; 2015; 9():3325-39. PubMed ID: 26170619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
    Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
    Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Castration-naive Metastatic Prostate Cancer.
    Hamilou Z; Baciarello G; Fizazi K
    Eur Urol Focus; 2017 Dec; 3(6):518-521. PubMed ID: 29500136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.
    Shiota M; Eto M
    Int J Urol; 2016 May; 23(5):360-9. PubMed ID: 27062039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer.
    Shiota M; Kashiwagi E; Murakami T; Takeuchi A; Imada K; Inokuchi J; Tatsugami K; Eto M
    Urol Oncol; 2019 Mar; 37(3):180.e19-180.e24. PubMed ID: 30446464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.
    Kobayashi K; Okuno N; Arai G; Nakatsu H; Maniwa A; Kamiya N; Satoh T; Kikukawa H; Nasu Y; Uemura H; Nakashima T; Mikami K; Iinuma M; Tanabe K; Furukawa J; Kobayashi H
    Jpn J Clin Oncol; 2021 Apr; 51(4):544-551. PubMed ID: 33324967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
    Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
    Mizokami A; Kadono Y; Kitagawa Y; Izumi K; Konaka H
    Int J Urol; 2017 Aug; 24(8):566-572. PubMed ID: 28577511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
    de Wit R; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Ozatilgan A; Geffriaud-Ricouard C; Castellano D;
    N Engl J Med; 2019 Dec; 381(26):2506-2518. PubMed ID: 31566937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early use of chemotherapy in metastatic prostate cancer.
    Markowski MC; Carducci MA
    Cancer Treat Rev; 2017 Apr; 55():218-224. PubMed ID: 27720577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.